Clinical trials
Imaging clinical trials
Below are recruiting imaging clinical trials, each written for real people, not researchers. We’re tracking 2,164 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05759780Recruiting
Check how an eye probe measures tissue softness
This study uses a special eye/skin/gum imaging test to measure how tissues behave. It may help researchers improve noninvasive ways to understand eye and tissue health, and in some parts of the study, mild keratoconus.
Boston, MassachusettsAges 18–75 - NCT05756569RecruitingPhase 2
Enfortumab plus pembrolizumab for advanced bladder cancer variants
This trial studies enfortumab vedotin plus pembrolizumab (immunotherapy) for people with advanced bladder cancer that has a “variant” or non-urothelial subtype. It aims to shrink tumors and improve outcomes when standard options have not worked or are no longer enough.
Atlanta, GeorgiaAges 18 years+ - NCT05678894Recruiting
Hip and pelvic measurements study for younger adults
This study compares hip positioning (acetabular angle) with pelvic tilt in people with femoro-acetabular impingement and in healthy volunteers. It may help researchers better understand hip mechanics and how they relate to symptoms and planning for arthroscopy surgery.
LyonAges 18–50 - NCT05711615RecruitingPhase 1
Low-dose doxorubicin plus peposertib for advanced sarcoma
This Phase 1 trial tests a low dose of a common chemotherapy (liposomal doxorubicin) together with an anti-cancer drug called peposertib. It’s for people with advanced sarcoma that can’t be cured, aiming to find a safe dosing plan and see how well the treatment might work.
Los Angeles, CaliforniaAges 18 years+ - NCT05726058Recruiting
Imaging eye blood flow to assess glaucoma
This study uses special imaging to look at blood flow in the eye to help assess or better understand glaucoma. You may be eligible if you’re an adult with eye exams that fit the study’s specific eye-health and imaging requirements.
Baltimore, MarylandAges 18–88 - NCT05739149Recruiting
Ultrasound checks how chronic foot ulcers heal
This study tests a special ultrasound scan to see how chronic diabetic or venous foot ulcers are healing. The goal is to use the scan to better track wound improvement and guide care.
Rochester, MinnesotaAges 18 years+ - NCT05709782RecruitingPhase 2
MR-guided targeted radiation for limited-spine spinal metastasis
This Phase 2 study tests an MRI-guided radiation machine (an MR LINAC) to deliver very focused treatment to spine tumors. It may help by improving accuracy while treating up to a small number of spine levels affected by cancer.
Houston, TexasAges 18 years+ - NCT05057403Recruiting
Imaging study for adults with type 2 diabetes in the UK
This study uses medical scans (MRI) to better understand diabetes in the body, including the eyes, and how it may change over time. It may help improve how diabetes is monitored, especially for people with diabetic eye disease.
Didcot, OxfordshireAges 18 years+ - NCT04532489RecruitingEarly Phase 1
PET scan study using a cholesterol-tracking tracer in healthy adults
This early study tests how well a special PET scan tracer can show cholesterol movement in the body. It is for healthy adults who do not have known adrenal problems, and it aims to collect basic imaging safety and dose information.
Ann Arbor, MichiganAges 18 years+ - NCT04546126RecruitingEarly Phase 1
PET scan study tracking cholesterol movement in your body
This early study uses a special PET scan dye to see how cholesterol moves through the body. It is testing how the imaging works in healthy people and in people with adrenal gland hormone secretion problems, to better understand cholesterol handling.
Ann Arbor, MichiganAges 18 years+ - NCT05705531Recruiting
Cardiac MRI study of heart health after Hodgkin lymphoma treatment
This study looks at how certain blood-related “growth patterns” connect to long-term heart health after treatment for classical Hodgkin lymphoma. It may help doctors better predict who could develop heart problems and how to monitor them over time.
Mobile, AlabamaAges 7 years+ - NCT05703685RecruitingPhase 1
Imaging brain inflammation target in depression with PET
This Phase 1 study uses a PET brain scan tracer to see how a specific brain target (PDE4B) is involved in major depressive disorder (MDD). It’s mainly testing whether the imaging approach works and what it shows in people with depression who meet specific safety and medication rules.
Bethesda, MarylandAges 18–70 - NCT05691491RecruitingPhase 1/Phase 2
Temozolomide plus M1774 for advanced metastatic cancers
This Phase 1/2 trial tests a combination of temozolomide and M1774 to see how safe it is and whether it can help shrink advanced cancers that have spread. It focuses on certain tumor types and specific biomarker results, and it may be an option if standard treatments have been tried or aren’t possible.
Irvine, CaliforniaAges 18 years+ - NCT05687136RecruitingPhase 1
Study two targeted drugs for solid tumors with DNA repair changes
This Phase 1 trial tests how safe and effective two anti-cancer drugs (peposertib and tuvusertib) are for advanced solid tumors. It focuses on cancers with specific DNA repair and cell-growth gene changes, aiming to shrink tumors and improve outcomes when standard treatments have stopped working.
Bethesda, MarylandAges 18 years+ - NCT05687110RecruitingPhase 1
Testing novobiocin for tumors with DNA repair gene changes
This Phase 1 study tests whether novobiocin is safe and finds the best dose for people whose tumors have specific DNA repair gene mutations. It may help if your cancer is hard to treat with standard options, including certain patients who already tried PARP inhibitors.
Duarte, CaliforniaAges 18 years+ - NCT05675410RecruitingPhase 3
Testing two-drug treatment versus standard for Hodgkin lymphoma
This Phase 3 study compares today’s standard treatment for classic Hodgkin lymphoma with a new combination using brentuximab vedotin and nivolumab. The goal is to see which approach works better and is safe for newly diagnosed patients with early-stage disease.
Birmingham, AlabamaAges 5–60 - NCT05687123RecruitingPhase 1
Adding sunitinib to Lutathera for pancreatic neuroendocrine tumors
This early-phase study tests whether adding sunitinib (a targeted pill) to Lutathera (a radioactive treatment) works better for people with advanced pancreatic neuroendocrine tumors. It also checks safety, since this combination has not been widely studied yet.
Duarte, CaliforniaAges 18 years+ - NCT05706129RecruitingPhase 1/Phase 2
Testing targeted imaging and therapy for advanced solid tumors
This early-phase study tests two radioactive medicines that first help doctors see tumors and, in some parts of the study, treat them. It may help people with advanced, hard-to-remove cancers that have a specific tumor marker (CA IX).
MelbourneAges 18 years+ - NCT02840019Recruiting
MRI scans during pregnancy to study baby and placenta development
This study uses advanced MRI pictures of the fetus (the baby) and placenta to better understand normal development and possible problems. You may qualify if you’re between 18 and 40 weeks pregnant and can have the MRI safely.
Boston, MassachusettsAges 18–45 - NCT05703386Recruiting
Study MRI changes in small-vessel stroke disease
This study looks at how “small-vessel” changes in the brain develop after an ischemic stroke, using repeated MRI scans. It may help researchers better understand what causes these changes and how to track them over time.
Baltimore, MarylandAges 18 years+ - NCT05677490RecruitingPhase 3
Chemotherapy with or without immunotherapy for advanced stomach or esophagus cancer
This trial compares two chemotherapy combinations, with or without an immunotherapy drug called nivolumab, for people with advanced stomach, esophagus, or gastroesophageal junction cancer that cannot be removed by surgery. The goal is to see which treatment works better and if adding immunotherapy helps.
Birmingham, AlabamaAges 18 years+ - NCT05701176Recruiting
Imaging scan to see how anti–PD-1 changes lung cancer cells
This study uses special PET imaging to measure changes in a marker ([18F]F-AraG) in non-small cell lung cancer after starting anti–PD-1 treatment. It aims to learn whether these scan changes reflect how the cancer responds.
AmsterdamAges 18 years+ - NCT05642572RecruitingPhase 2
Test drug combinations for EGFR- and MET-changed lung cancer
This Phase 2 trial tests combinations of targeted medicines to treat advanced non-small cell lung cancer (NSCLC) that has changes in both EGFR and MET genes. It is for people whose cancer continued to grow even after treatment with osimertinib, the most recent therapy.
Daphne, AlabamaAges 18 years+ - NCT05658913Recruiting
Tau PET/CT scan study for people in an ongoing cohort
This study uses a special brain scan (tau PET/CT) to look for a protein called tau, and it ties the scan results to information collected in an existing research program. It may help researchers better understand brain changes over time.
Boston, MassachusettsAges 18–120
Hear when a new Imaging trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for imaging?
- Yes. Clin2 currently lists 2,164 recruiting imaging studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a imaging trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a imaging trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.